UFP Technologies: New CEO, Resolved Backlog, and a Record Quarter Signal a New Chapter
Broad-based growth, an accelerated resolution of operational issues, and a robust M&A pipeline position the custom medical device maker for the next phase.
UFPT · Earnings Call · 2026-08-04
A Clean Slate: New CEO, Record Results
The second quarter of 2026 marked a transition for UFP Technologies. New CEO Mitch Rock, in his first earnings call, delivered a "company record" adjusted EPS of $2.92, with sales up 15.1% and organic growth of 12.4%. The quarter was notable for its breadth: “Growth remained broad-based throughout the portfolio with our top 5 customers growing 14.7%, while the balance of our MedTech business grew 19.7%.” — Mitchell Rock, President and Chief Executive Officer · 2026-08-04 This diversification is a key shift from a business historically concentrated on its largest customer, Intuitive Surgical, and signals that the end markets and existing customers are providing a wider base. The MedTech business is now more balanced, reducing the reliance on a single contract. Management highlighted that growth was driven by "a diverse set of customer programs, the breadth of our businesses and the continued execution of our teams across the organization."Operational Resolution and the New Program Ramp
A central theme of the past year was the labor inefficiency and backlog at the AJR (safe patient handling) facility. Management has now declared that issue resolved: “We are through the backlog. So we would no longer talk about the backlog. We are through the labor issue. So we are fully ramped in St. Charles and the platform continues to grow.” — Mitchell Rock, President and Chief Executive Officer · 2026-08-04 However, the transfer of a third program to the Dominican Republic remains delayed pending customer qualification, a nuance that tempers the enthusiasm. This is a continuation of prior operational friction; in the Q3 2025 call, the previous CEO acknowledged the issue directly: “Yes, you're exactly correct. The underperformance was related to AJR because the labor inefficiency is causing us to ship less product.” — R. Jeffrey Bailly, Chief Executive Officer and Chairman · 2025-08-05 The subsequent quarters have seen progress, but the DR transfer slowdown shows the complexity of moving production while maintaining quality. Meanwhile, the new program launches—two in robotic surgery and one in infection prevention—are ramping as expected. The CEO noted: “The broad growth across the platform really demonstrates the durability and diversity of UFP's exposure to multiple products in multiple markets.” — Mitchell Rock, President and Chief Executive Officer · 2026-08-04 The company reaffirmed that these programs will contribute an eight-figure revenue addition in 2027. This ramp was flagged earlier in the year; the CFO said on the Q1 call: “3 of the 4 programs are brand new and one was a transfer.” — Ronald Lataille, Chief Financial Officer · 2026-05-05 That distinction matters because the internal transfer doesn't add net new revenue, but the three new programs will be meaningful contributors.Strategic Investments and Cost Pressures
SG&A rose $4.1 million partly due to back-office investments and CEO transition costs, but management indicated this is the new normal. "We have made investments. I think that there's ultimately a little cushion in there because there's temporary costs that will cycle through due to the CEO transition," said CFO Ron Lataille. “The current level is approximately where we should be going forward.” — Ronald Lataille, Chief Financial Officer · 2026-08-04 Meanwhile, the conflict in Iran is causing inflationary pressure on petroleum-based raw materials, though the company expects to pass these through. This is a more immediate headwind than the broader market's focus on conflict in Iran. The M&A pipeline is described as robust with 5-10 opportunities in the $5-30M EBITDA range, reflecting a disciplined approach to growth. The CEO stated: “We were looking at anywhere from 5 to 10 opportunities that range from $5 million to $30 million of EBITDA.” — Mitchell Rock, President and Chief Executive Officer · 2026-08-04 This aligns with the company's long-stated strategy of using acquisitions to drive half of its growth.Fundamentals Confirm a Maturing Business
Looking at the fundamentals, revenue has grown from ~$37M in 2016 to over $150M in recent quarters, while gross margin has improved steadily. Gross margin has trended up from 22-27% in 2016 to consistently above 28% in 2025-2026, reflecting mix and scale. Operating margin has been more volatile, but the company's ability to generate record EPS despite the one-time costs suggests strong underlying profitability. The company exited the quarter with leverage below 1x, providing ample flexibility for M&A. Overall, UFP's story is one of maturation: a founder-era CEO handing off to a seasoned insider, a customer concentration giving way to a broader portfolio, and operational disruptions being resolved. The market has clearly voted positively, with the stock up over 50% in the last 90 days, though still below its 2024 peak. As new CEO Mitch Rock summed up:If there's one takeaway from today, it's the strength of the UFP platform. Our growth is broad-based. Our end markets remain attractive, and our operating businesses are deeply embedded with customers across multiple medical applications.